Medical Daily | 'Biosimilar' drug ruling to hit Big Pharma Financial Times The decision is the first time in the industrialised world that the multibillion-dollar annual market for monoclonal antibodies has been opened to generic producers, after a long period during which investors assumed such complex “large molecule ... European Agency Favors Remicade Biosimilars First Copy of J&J's $6 Billion Remicade Wins EMA Backing A Pivotal Decision By European Drug Regulators on Remicade Is Unlikely To ... |
